Cartilage Injury of the Knee (AANA20)-Should We Still Consider MFX to Treat Surface Lesions in 2020-Dr. Kevin F. Bonner, M.D.

Should We Still Consider MFX to Treat Surface Lesions in 2020-Dr. Kevin F. Bonner, M.D.

Video Transcription

Video Summary

Kevin Bonner discusses the role of microfracture or marrow stimulation for treating surface cartilage lesions. He highlights its popularity due to simplicity, low morbidity, and cost, especially in younger patients with smaller femoral condyle lesions. Outcomes vary with prognostic factors like lesion etiology, location, and patient age. Fibrocartilage formed may be durable enough for many but has limitations. While microfracture is less invasive than alternatives like ACI or allografts, failure rates can exceed 30%. New adjuncts like micronized articular cartilage show promise but lack extensive clinical validation. Ultimately, treatment choice requires individualized risk-benefit analysis considering patient preferences and lesion specifics.

Keywords

microfracture

marrow stimulation

surface cartilage lesions

fibrocartilage durability

treatment outcomes